More than 1,200 clinical trials across the globe were disrupted due to the COVID-19 pandemic related lockdowns and restrictions on movement. Shortages in personal protective equipment across the world is affecting both clinical workers and trial participants.
GlobalData had conducted a survey to identify the primary business concerns of pharmaceutical companies related to COVID-19 outbreak.
Go deeper with GlobalData
Primary Business Concerns Related to the COVID-19 Outbreak
Clinical trial disruption emerged as the biggest business concern of the industry due to the pandemic according to 26% of the respondents. Safety of patients recruited in the trials and employee safety in such programmes were others concerns expressed by 19% and 17% of the respondents respectively.
Around 11% of the companies highlighted contract research organisation (CRO) disruptions, while another 11% said that impact on supply chain was their primary concern related to the coronavirus outbreak.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBusiness development and capital raising were primary concerns for 10% and 5% of the respondents.
A minority of 1% of the surveyed companies expressed other concerns.
The analysis is based on responses received from the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.
